Monika Engelhardt - Concepedia

Author

Monika Engelhardt

University Medical Center Freiburg ORCID

Also Known As

Berger, Dietmar P, Engelhardt, M., Engelhardt, Monika, M ENGELHARDT, M Engelhardt, M. Engelhardt, M. M. Engelhardt, Monika Engelhardt, Monika Martha Engelhardt, Nathalie Duerinckx

583

Publications

14.7K

Citations

H-Index

150

Concepts

All Affiliations

University Medical Center Freiburg University of Freiburg Universitätsklinikum Würzburg Universität Hamburg University Medical Center Hamburg-Eppendorf

About

Monika Engelhardt is an author at University Medical Center Freiburg specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	62	4.8K
2	Health Sciences	20	26	2.2K
3	Engineering	1	1	130
4	Natural Sciences	1	1	34
5	Nursing	1	1	59

Monika Engelhardt

131

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, New England Journal of Medicine	2019	655
Strength and muscle mass loss with aging process. Age and strength loss Karsten Keller, Monika Engelhardt Muscles Ligaments and Tendons Journal	2019	490
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications Evangelos Terpos, Martina Kleber, Monika Engelhardt, Haematologica Bone DiseaseHematological MalignancyZoledronic AcidEuropean Myeloma NetworkMedicine	2015	391
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Essential role of stromally induced hedgehog signaling in B-cell malignancies Christine Dierks, Jovana Grbic, Katja Zirlik, Nature Medicine Tumor BiologySignaling PathwayEssential RoleCell RegulationMalignant Blood Disorder	2007	321
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro, The Lancet Oncology Hematological MalignancyOncologyDexamethasone Versus PomalidomideMetronomic TherapyImmunology	2021	316
Telomerase Regulation, Cell Cycle, and Telomere Stability in Primitive Hematopoietic Cells Monika Engelhardt, Rakesh Kumar, Juan Albanell, Blood	1997	287
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients Monika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, Haematologica	2017	260
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, The Lancet Haematology Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor	2019	249
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, The Lancet Haematology Hematological MalignancyMedicineImmunologyClinical TrialsHematology	2019	237

Page 1